Characteristics of Patients Transplanted in Chronic Phase, n = 152
| Pretreatment . | Chemotherapy n = 66 . | IFN Discontinued ≤90 Days Before BMT n = 50 . | IFN Discontinued >90 Days Before BMT n = 36 . |
|---|---|---|---|
| Median age at diagnosis, yr | 34.7 (15.0-50.3) | 34.8 (10.4-55.8) | 34.1 (22.2-53.0) |
| Median age at BMT, yr | 36.5 (15.3-53.4) | 36.2 (12.8-58.2) | 36.7 (23.4-55.4) |
| Sex ratio | 76% Male | 60% Male | 67% Male |
| Median interval from diagnosis to BMT, yr | |||
| Study I | 1.4 (0.2-7.0); n = 44 | 1.9 (0.5-4.0); n = 22 | 1.7 (0.8-7.0); n = 12 |
| Study II | 1.3 (0.6-4.3); n = 22 | 1.5 (0.4-4.1); n = 28 | 2.4 (0.6-5.0); n = 24 |
| Median observation time after BMT, yr | |||
| All patients | 3.6 (0.1-13.5) | 1.1 (0.04-9.2) | 1.9 (0.1-8.8) |
| Living patients | 6.8 (1.2-13.5); n = 37 | 4.3 (1.5-9.2); n = 23 | 2.4 (0.7-8.8); n = 28 |
| Sokal score | |||
| Low | 47% | 44% | 47% |
| Intermediate | 42% | 28% | 25% |
| High | 11% | 28% | 28% |
| New IFN score | |||
| Low | 68% | 54% | 61% |
| Intermediate | 30% | 28% | 36% |
| High | 2% | 18% | 3% |
| Donor: | |||
| Related | 80% | 70% | 44% |
| Unrelated | 20% | 30% | 56% |
| Donor sex | 50% Male | 67% Male | 65% Male |
| Median donor age, yr | 34 (11-69); n = 57 | 39 (10-59); n = 41 | 36 (22-64); n = 28 |
| Median time of transplant | 1/91 (8/84-7/97) | 8/93 (4/87-9/96) | 10/94 (5/88-8/97) |
| Study I | 5/89 (8/84-9/94); n = 44 | 6/91 (4/87-1/94); n = 22 | 6/91 (5/88-6/97); n = 12 |
| Study II | 8/94 (1/92-7/97); n = 22 | 8/94 (1/92-9/96); n = 28 | 11/95 (12/91-8/97); n = 24 |
| Pretreatment . | Chemotherapy n = 66 . | IFN Discontinued ≤90 Days Before BMT n = 50 . | IFN Discontinued >90 Days Before BMT n = 36 . |
|---|---|---|---|
| Median age at diagnosis, yr | 34.7 (15.0-50.3) | 34.8 (10.4-55.8) | 34.1 (22.2-53.0) |
| Median age at BMT, yr | 36.5 (15.3-53.4) | 36.2 (12.8-58.2) | 36.7 (23.4-55.4) |
| Sex ratio | 76% Male | 60% Male | 67% Male |
| Median interval from diagnosis to BMT, yr | |||
| Study I | 1.4 (0.2-7.0); n = 44 | 1.9 (0.5-4.0); n = 22 | 1.7 (0.8-7.0); n = 12 |
| Study II | 1.3 (0.6-4.3); n = 22 | 1.5 (0.4-4.1); n = 28 | 2.4 (0.6-5.0); n = 24 |
| Median observation time after BMT, yr | |||
| All patients | 3.6 (0.1-13.5) | 1.1 (0.04-9.2) | 1.9 (0.1-8.8) |
| Living patients | 6.8 (1.2-13.5); n = 37 | 4.3 (1.5-9.2); n = 23 | 2.4 (0.7-8.8); n = 28 |
| Sokal score | |||
| Low | 47% | 44% | 47% |
| Intermediate | 42% | 28% | 25% |
| High | 11% | 28% | 28% |
| New IFN score | |||
| Low | 68% | 54% | 61% |
| Intermediate | 30% | 28% | 36% |
| High | 2% | 18% | 3% |
| Donor: | |||
| Related | 80% | 70% | 44% |
| Unrelated | 20% | 30% | 56% |
| Donor sex | 50% Male | 67% Male | 65% Male |
| Median donor age, yr | 34 (11-69); n = 57 | 39 (10-59); n = 41 | 36 (22-64); n = 28 |
| Median time of transplant | 1/91 (8/84-7/97) | 8/93 (4/87-9/96) | 10/94 (5/88-8/97) |
| Study I | 5/89 (8/84-9/94); n = 44 | 6/91 (4/87-1/94); n = 22 | 6/91 (5/88-6/97); n = 12 |
| Study II | 8/94 (1/92-7/97); n = 22 | 8/94 (1/92-9/96); n = 28 | 11/95 (12/91-8/97); n = 24 |